Which feature best distinguishes COX-2 selective inhibitors from non-selective NSAIDs in terms of their adverse effect profile?

Explanation

## Distinguishing Feature: GI Safety Profile **Key Point:** COX-2 selective inhibitors (coxibs) have a markedly lower incidence of gastric ulceration and GI bleeding compared to non-selective NSAIDs, which is their primary pharmacological advantage. ### Mechanism of GI Protection Non-selective NSAIDs inhibit both COX-1 and COX-2: - COX-1 inhibition → ↓ PGE₂ and PGI₂ in gastric mucosa → loss of cytoprotection → ulcer risk - COX-2 inhibition → anti-inflammatory and analgesic effects COX-2 selective inhibitors spare gastric COX-1, preserving mucosal prostaglandins and reducing ulcer incidence by ~50% compared to non-selective NSAIDs [cite:KD Tripathi 8e Ch 12]. ### Comparative Safety Profile | Feature | Non-selective NSAIDs | COX-2 Inhibitors | |---------|----------------------|------------------| | GI ulceration risk | High (1–3% annually) | Low (0.5–1% annually) | | Cardiovascular risk | Lower | Higher (thrombotic events) | | Renal toxicity | Present | Present (dose-dependent) | | Anti-inflammatory efficacy | Equivalent | Equivalent | **High-Yield:** The cardiovascular risk of coxibs (MI, stroke) emerged post-market and led to withdrawal of rofecoxib (Vioxx) in 2004. This is a **trade-off**: better GI safety but worse CV safety. **Clinical Pearl:** In patients with high GI risk (age >65, PUD history, concurrent corticosteroids), COX-2 inhibitors ± PPI are preferred. In those with CV risk factors, non-selective NSAIDs ± PPI are safer. **Warning:** Neither class eliminates renal toxicity — both inhibit renal COX-2, risking acute kidney injury, hyperkalemia, and fluid retention, especially in volume-depleted or elderly patients.